Magenta Therapeutics Inc logo


Magenta Therapeutics Inc


Earnings Summary

Net Profits


Net Profits:

Magenta Therapeutics Inc’s net profit fell -2.03% since last year same period to $-17.27Mn in the Q2 2022. On a quarterly growth basis, Magenta Therapeutics Inc has generated 24.75% jump in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Magenta Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

Magenta Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.33 - a -6.45% fall from last quarter’s estimates.

EPS Estimate Current Year:

Magenta Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.33.

Key Ratios

Key ratios of the Magenta Therapeutics Inc post its Q2 2022 earnings

Return on Assets (ROA)
Return on Equity (ROE)
Dividend Per Share (DPS)


Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Magenta Therapeutics Inc’s return on assets (ROA) stands at -0.25.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Magenta Therapeutics Inc’s return on equity (ROE) stands at -0.45.

Dividend Per Share (DPS):

Magenta Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.

Magenta Therapeutics Inc
Cambridge, Massachusetts, US
Health Technology
Jason Gardner